Quick Answer
Damora Therapeutics, Inc. reported Diluted EPS of $3.98 per share for fiscal year 2025.
Damora Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $3.98 | +121.5% |
| 2024 | -$18.53 | +48.6% |
| 2023 | -$36.08 | -1384.8% |
| 2022 | -$2.43 | -18.5% |
| 2021 | -$2.05 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.36 | +30.4% | +9.2% |
| June 30, 2025 | -$2.60 | +47.2% | -35.4% |
| March 31, 2025 | -$1.92 | +62.0% | +43.4% |
| September 30, 2024 | -$3.39 | +54.8% | +31.1% |
| June 30, 2024 | -$4.92 | -1100.0% | +2.6% |
| March 31, 2024 | -$5.05 | -890.2% | +32.7% |
| September 30, 2023 | -$7.50 | -1288.9% | -1729.3% |
| June 30, 2023 | -$0.41 | +38.8% | +19.6% |
- Damora Therapeutics, Inc. showed an increase of +121.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Damora Therapeutics, Inc.’s diluted eps has grown by 294.1% (from $2.05 per share (loss) to $3.98 per share).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: